PILA PHARMA AB
Clinical-stage biotech developing an oral TRPV1 antagonist for diabetes and obesity.
PILA | ST
Overview
Corporate Details
- ISIN(s):
- SE0015988274
- LEI:
- 6488Z7WG18Q0ZN0V0262
- Country:
- Sweden
- Address:
- Norra Vallgatan 72, 211 22 Malmö
- Website:
- https://pilapharma.com/
Description
PILA PHARMA AB is a clinical-stage biotechnology company focused on developing treatments for metabolic diseases. The company is pioneering the development of XEN-D0501, a potential first-in-class, oral TRPV1 antagonist. This drug candidate is being investigated for the treatment of type 2 diabetes and, more recently, obesity. The company's approach aims to provide a novel, oral therapeutic alternative to address the growing global prevalence of these conditions by targeting the TRPV1 mechanism, also known as the 'chili-receptor'.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all PILA PHARMA AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for PILA PHARMA AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for PILA PHARMA AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
